More on NUVB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.70 |
|
|||
| Open | $4.62 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $4.66 | ||||
| Day Low | $4.44 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 3,190,760 | ||||
- Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
- Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens After Solid Q3, Setup for FY Beat
- U.S. biotech SMids: Q3 earnings preview
- Citi initiates Nuvation Bio coverage with Buy rating, $12 target
- FDA updates Nuvation Bio's IBTROZI label with 49.7-month response data
- Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
- Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens on ROS1 TKI Competitive Profile
- Nuvation Bio presents Ibtrozi subgroup data at lung cancer conference
- Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Canc
- Nuvation Bio to Participate in Upcoming Investor Conferences
Entities mentioned with NUVB
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
